Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2020-01-06 Net Asset Value
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Net Asset Value Classification · 95% confidence The document is titled "BILAN ANNUEL DU CONTRAT DE LIQUIDITÉ CONTRACTÉ AVEC LA SOCIÉTÉ DE BOURSE GILBERT DUPONT" (Annual Balance Sheet of the Liquidity Contract with Gilbert Dupont Stock Brokerage Firm). It details the activity (purchases and sales of shares) and the resulting balance (number of shares and cash balance) in the liquidity account as of December 31, 2019, comparing it to the previous semi-annual balance. This type of regular reporting on market-making or liquidity provision activities, especially when presented as a formal balance update, often falls under regulatory reporting related to market operations or capital structure maintenance. Since it is a specific report detailing the status of a liquidity contract, it is not a standard 10-K, ER, or IR. It is a specific financial/operational update. Given the options, it most closely relates to updates on capital structure or financing activities, but it is specifically about a liquidity contract balance. It is not a general regulatory filing (RNS) nor a general capital change (CAP). However, liquidity contracts are often related to share stabilization or market support, which touches upon share transactions. Since there is no specific code for 'Liquidity Contract Report', and it details transactions and balances related to the company's shares, it is best classified as a specific operational/financial disclosure. Given the options, 'Capital/Financing Update' (CAP) is the closest fit as liquidity contracts are financing tools, or it could be a miscellaneous regulatory filing (RNS). Since it is a formal 'Bilan Annuel' (Annual Balance) of a specific contract, and not a general announcement of a financing round, I will lean towards the most specific category that covers share-related activities or general regulatory disclosures. As it details share transactions and balances, and is not a standard report, 'Transaction in Own Shares' (POS) is plausible if the liquidity provider is acting on behalf of the company for buybacks, but the text doesn't explicitly state buybacks, only transactions under a contract. Given the lack of a perfect fit, and its nature as a formal, periodic report on a specific financial arrangement, 'RNS' (Regulatory Filings - fallback) is a safe classification, but let's re-evaluate. This is a report on the status of a liquidity agreement, which is a form of capital management/share activity. Since it is a formal report detailing share movements and balances, and not just a brief announcement, it is more substantial than an RPA. I will classify it as a specific operational report that doesn't fit the main categories, defaulting to RNS, as it is a formal disclosure. Revisiting the definitions: It is a formal report detailing share transactions and balances related to a liquidity agreement. This is a specific operational disclosure. It is not a dividend (DIV), director dealing (DIRS), or major shareholding (MRQ). It is most akin to a specialized report on share activity. Since 'RNS' is the fallback for miscellaneous filings, and this is a very specific, non-standard report type, RNS is the most appropriate choice.
2020-01-06 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is explicitly titled "*PRESS RELEASE*" and announces the receipt of the "2019 PRIX GALIEN AWARD" for the product HENSIFY®. It details product information, clinical trial progress, and includes contact information and a disclaimer typical of corporate news releases. This format strongly suggests an announcement intended for immediate public dissemination regarding a significant, non-periodic event (an award). This fits best under the general category for regulatory announcements or news releases that don't fit a specific financial report type. Since it is a press release announcing news rather than a formal financial filing (like 10-K, IR, or ER), and it doesn't fit other specific categories like M&A (TAR) or Director's Dealing (DIRS), the most appropriate fallback is Regulatory Filings (RNS), which often encompasses general corporate news releases distributed to the market.
2019-12-16 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces that Nanobiotix received the 2019 Galien Prize for its product Hensify®. It details the product, the significance of the award, ongoing clinical trials, and includes standard company information and contact details. This format—a formal announcement of a specific, non-periodic event (an award) or achievement, rather than a comprehensive financial report (like 10-K or IR) or a standard regulatory filing update—best fits the category for general corporate news or announcements that don't fit other specific financial reporting codes. Since it is a press release announcing a significant, non-financial milestone (an award), it is most appropriately classified as a general Regulatory Filing (RNS) as it is a public disclosure, or potentially a general Investor Relations document, but RNS serves as the best general announcement fallback when specific categories like ER, DIV, or CAP do not apply. Given the context of a premium database, this is a standard corporate news release.
2019-12-16 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly Information Relative to the Total Number of Voting Rights and Shares Comprising the Share Capital). It explicitly references French regulatory articles (Code de commerce and Règlement Général de l'Autorité des Marchés Financiers - AMF) and provides a table detailing the total number of shares and voting rights as of November 30, 2019. This type of regular disclosure regarding the total share capital and voting rights is a specific regulatory requirement in France, often related to major shareholding notifications or capital structure updates. Given the options, this most closely aligns with a notification regarding changes in significant share ownership or capital structure reporting, which falls under Major Shareholding Notification (MRQ) or potentially a general Regulatory Filing (RNS). Since it is a specific, recurring report on the total number of shares/votes, MRQ is the most precise fit, as these reports are often triggered when thresholds are crossed or reported monthly/quarterly to track ownership changes, even if the document itself is just a statement of the current total.
2019-12-05 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is explicitly titled "*PRESS RELEASE*" and announces new pre-clinical study results presented at the SITC 2019 meeting. It contains key highlights, scientific data summaries, background on the product (NBTXR3), and contact information, which are characteristic features of an Earnings Release (ER) or a general press announcement regarding scientific/operational updates. Since it is a press release announcing scientific data rather than a comprehensive financial report (10-K, IR) or a transcript (CT), the most appropriate classification is Earnings Release (ER), as these often accompany or precede formal financial reporting periods with key operational/scientific milestones. It is not a formal regulatory filing like a 10-K or a specific report like an AR or SR.
2019-11-12 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 85% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces "NANOBIOTIX ANNONCE DE NOUVEAUX RÉSULTATS DANS L'ÉTUDE PRÉCLINIQUE EN IMMUNO-ONCOLOGIE AU SITC 2019". It details scientific findings from a preclinical study presented at a conference (SITC 2019). This format—a brief announcement summarizing key results and developments, often released outside of mandatory periodic filings—is characteristic of an Earnings Release (ER) if it were financial results, or more generally, a press release announcing corporate or scientific progress. Since the content is focused on scientific data presentation and collaboration results, and it is explicitly a press release, it is best classified as an Earnings Release (ER) if it were quarterly results, but here it is a scientific update. Given the options, this type of announcement summarizing key operational/scientific milestones is often grouped with initial results announcements. However, since it is a press release announcing scientific data rather than financial earnings, and it is not a formal regulatory filing like a 10-K or IR, the most fitting category for a general, non-financial, non-statutory announcement that conveys important company news is often the Earnings Release category (ER) if we interpret it broadly as a 'results announcement', or Regulatory Filings (RNS) as a fallback. Given the strong emphasis on 'results' (even if preclinical), ER is plausible, but RNS is the safest catch-all for non-standard announcements. Since it is a press release announcing scientific progress, and not a formal financial report, it does not fit 10-K, IR, or MDA. It is not a proxy (DEF 14A/PSI) or a capital event (CAP/SHA). It is a general corporate announcement. I will classify it as an Earnings Release (ER) as it announces 'results', or RNS as the general regulatory announcement fallback. Given the context of financial reporting databases, scientific press releases announcing data are often categorized under ER or RNS. I will choose ER as it announces 'results' from a study, which is analogous to announcing earnings results in structure. FY 2019
2019-11-12 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.